By Stephen Nakrosis
Shares of Allurion Technologies were trading higher in the after-hours market following news the company would initiate a clinical study on the combination of certain weight-loss drugs and its Allurion program with the goal of improving muscle mass.
In Thursday's after-hours market, the company's shares had risen 68% to trade at $6.24. Volume in the late session topped 4.3 million shares. Shares finished the day's regular session with a 21% gain at $3.70.
Allurion said it planned to study GLP-1 agonists in combination with its Allurion Program. The company said previous studies in patients undergoing GLP-1 therapy showed reductions in lean mass as part of the overall weight loss. Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass.
Shantanu Gaur, the founder and chief executive of Allurion, said the goal of the study would be to prove that combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy would lead to patients losing significant weight while increasing muscle mass and improving overall body composition.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 23, 2025 18:22 ET (23:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。